WO2018103734A1 - Récepteur d'antigène chimère, son utilisation et son procédé de préparation - Google Patents
Récepteur d'antigène chimère, son utilisation et son procédé de préparation Download PDFInfo
- Publication number
- WO2018103734A1 WO2018103734A1 PCT/CN2017/115184 CN2017115184W WO2018103734A1 WO 2018103734 A1 WO2018103734 A1 WO 2018103734A1 CN 2017115184 W CN2017115184 W CN 2017115184W WO 2018103734 A1 WO2018103734 A1 WO 2018103734A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- seq
- chimeric antigen
- antigen receptor
- car
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 130
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 253
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 28
- 239000013598 vector Substances 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 285
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 70
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 69
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 68
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 64
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 62
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 59
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 230000011664 signaling Effects 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 230000000139 costimulatory effect Effects 0.000 claims description 31
- 239000003446 ligand Substances 0.000 claims description 31
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 29
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 22
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 21
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 21
- 210000004881 tumor cell Anatomy 0.000 claims description 18
- -1 ICOS Proteins 0.000 claims description 10
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 6
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 62
- 241000713666 Lentivirus Species 0.000 description 46
- 230000002147 killing effect Effects 0.000 description 37
- 239000005089 Luciferase Substances 0.000 description 33
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 238000003501 co-culture Methods 0.000 description 22
- 238000001994 activation Methods 0.000 description 20
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 102000000588 Interleukin-2 Human genes 0.000 description 18
- 108010002350 Interleukin-2 Proteins 0.000 description 18
- 238000004806 packaging method and process Methods 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 230000003834 intracellular effect Effects 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 239000013613 expression plasmid Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 102000048362 human PDCD1 Human genes 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 10
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 208000021601 lentivirus infection Diseases 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000012124 Opti-MEM Substances 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012096 transfection reagent Substances 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 102220547700 Carcinoembryonic antigen-related cell adhesion molecule 3_N74G_mutation Human genes 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000007783 downstream signaling Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000005008 immunosuppressive cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 108010056030 retronectin Proteins 0.000 description 4
- 102200109609 rs281875332 Human genes 0.000 description 4
- 102200062504 rs398123317 Human genes 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000043850 Programmed Cell Death 1 Ligand 2 Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102220266304 rs1170214930 Human genes 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007862 touchdown PCR Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Definitions
- the present invention relates to a novel chimeric antigen receptor (CAR), its use and a preparation method.
- the chimeric antigen receptor can specifically bind to the ligand PD-L1 and/or PD-L2 of the immunosuppressive receptor PD-1; T cells (CAR T cells) expressing the chimeric antigen receptor can be specific Killing target cells expressing PD-L1 and/or PD-L2 ligands.
- the regulation of T cell function by the human immune system includes a positive activation pathway and a negative inhibition pathway.
- activation of T cells requires two signals, including a first signal and a second signal.
- the first signal is triggered by the binding of a major histocompatibility complex (MHC)-antigen polypeptide complex on the surface of the antigen presenting cell (APC) membrane to the T cell receptor (TCR) on the surface of the T cell membrane, and the second signal is composed of the antigen.
- MHC major histocompatibility complex
- APC antigen presenting cell
- TCR T cell receptor
- the costimulatory protein presented on the surface of the cell membrane is triggered by binding to the corresponding co-receptor protein on the surface of the T cell.
- Co-receptor proteins include CD28, OX40, and CD137.
- the T cell receptor transmits a signal triggered by the TCR/CD3 transmembrane protein complex, and CD3 ⁇ plays an important role in this process.
- T cells After T cells are activated by the forward pathway, they can be abundant. Amplifies and releases cytokines that promote immune response and kills target cells.
- receptor PD-1 is the most important co-inhibitory protein in the body.
- Receptor PD-1 is a type I transmembrane protein expressed in activated T cells, B cells, activated NK cells, monocytes, and immature Langerhans cells.
- receptor PD-1 has two ligands, PD-L1 and PD-L2. Under physiological conditions, binding of the receptor PD-1 expressed by T cells to the ligand PD-L1 or PD-L2 negatively regulates T cell proliferation and cytokine production.
- a variety of tumor cells utilize this negative regulatory mechanism, which directly upregulates the expression of ligand PD-L1 or PD-L2 through transcription, post-transcriptional regulation, and epigenetic mechanisms.
- the ligand PD-L1 or PD-L2 on the surface of tumor cells binds to receptor PD-1 on T cells, inhibiting the activation of T cells, thereby avoiding attack by immune cells.
- the ligand PD-L1 or PD-L2 is highly expressed in various tumor tissues, including non-small cell lung cancer, melanoma, renal cell carcinoma, prostate cancer, breast cancer, glioma, etc., ligand PD-L1 or PD-L2. Binding to the receptor PD-1 on T cells depletes T cell function, loses proliferation and kills tumor cells.
- Blocking the receptor PD-1 binding to the ligand PD-L1 or PD-L2 can be used as a tumor immunotherapy, ie, checkpoint therapy, by blocking PD-1 mediated negative regulatory signals, T The cells restore activity, thereby enhancing the immune response to cancer cells.
- drugs that block PD-1/PD-L1 or PD-L2 binding are mainly monoclonal antibodies.
- the drugs that block the PD-1 signaling pathway are Opdivo (Nivolumab) from Bristol-Myers Squibb (BMS) and Keytruda (Pembrolizumab) from Merck Sharp & Dohme.
- Other drugs at the stage of research include Pidilizumab (CT-011).
- Adoptive cellular immunotherapy is also a method of tumor immunotherapy, and the use of chimeric antigen receptor T cells (CAR T cells) to kill cancer cells is one of the adoptive cell immunotherapy methods.
- the chimeric antigen receptor (CAR) comprises an scFv fragment (or antigen recognition domain) which specifically recognizes a tumor antigen, and the hinge region, the transmembrane region and the intracellular signal domain are sequentially connected to each other.
- the antigen on the target cell binds to the antigenic domain of the chimeric antigen receptor (CAR)
- the signal is transmitted to the cell through the hinge region and the transmembrane region, and the intracellular signal domain converts the signal into an activation signal, activating the effector cell.
- CD19ZCAR and PD-1CD28 proteins are co-expressed in T cells to kill target cancer cells, that is, the chimeric antigen receptor of CD19Z on the surface of T cells binds to CD19 on the surface of tumor cells, thereby recognizing and killing CD19 antigen.
- Tumor cells at the same time, the PD-1CD28 protein expressed on the surface of T cells competes with endogenous PD-1 on the surface of T cells to bind to PD-L1 or PD-L2 molecules on the surface of tumor cells, and converts the inhibition signal into a stimulation signal.
- CD19ZCAR and PD-1CD28 synergistically achieve the killing effect on tumor cells.
- this protocol cannot kill tumor cells or immunosuppressive cells expressing the ligand PD-L1 or PD-L2, and the microenvironment of tumor immunosuppression still exists, so there is still a need for a more efficient method for killing cancer cells by immunotherapy.
- the present invention provides a chimeric antigen receptor (CAR) which binds to PD-L1 and/or PD-L2 on the surface of a target cell and activates a signaling structure through it to enable a T expressing CAR
- CAR chimeric antigen receptor
- the cells activate, massively expand, release cytokines that promote immune responses and kill target cells. This reverses the negative inhibition pathway produced by the binding of T cells that do not express this CAR to PD-L1 and/or PD-L2 on the surface of target cells.
- a chimeric antigen receptor of the invention comprising: (i) a domain having a binding to a ligand PD-L1 or PD-L2; (ii) Hinge region; (iii) transmembrane domain; (iv) costimulatory signaling domain; (v) CD3 ⁇ signaling domain.
- the domain (i) has a domain that binds to an immunosuppressive receptor PD-1 ligand PD-L1 and/or PD-L2 molecule.
- the chimeric antigen receptor domain (i) of the present invention may be a domain that binds to a ligand in a PD-1 molecule, or an scFv of an antibody of PD-L1 or PD-L2.
- the antibody can be from a human or animal source, including a murine source.
- domain (i) has a domain that binds to ligand PD-L1.
- the chimeric antigen receptor domain (i) of the invention is part of a PD-1 protein and has at least 90%, 92%, 95%, 96%, 97% of the sequence of SEQ ID No: 1. , 98%, 99% or 100% identity, more preferably the sequence shown in SEQ ID No: 1.
- the chimeric antigen receptor is capable of binding to cells expressing the ligand PD-L1 or PD-L2, or cells expressing the PD-L1 and PD-L2 ligands.
- the domain (i) on the PD-1 molecule has the sequence set forth in SEQ ID No: 2 or 3.
- the hinge region comprises at least one of: a hinge region of CTLA4, a hinge region of CD28, a hinge region of CD7, a hinge region of IgG1, a hinge region of IgG4, a hinge region of IgD, a hinge region of CD7, CD8 ⁇
- the hinge area or the hinge area of PD-1 is derived from a human; more preferably, the hinge region is the hinge region SEQ ID No: 4 of hPD-1 (human PD-1).
- the hinge region comprises a hinge region of PD-1 and a hinge region of CD8 ⁇ having the sequence set forth in SEQ ID No: 5. In another embodiment, the hinge region has the sequence set forth in SEQ ID No: 6.
- the transmembrane domain comprises at least one of: a transmembrane domain of CD4, a transmembrane domain of CD7, a transmembrane domain of CD8 ⁇ , a transmembrane domain of CD28, a transmembrane domain of CD134, a span of CD137 Membrane domain, transmembrane domain of Fc ⁇ RI ⁇ or transmembrane domain of H2-Kb.
- the transmembrane region is derived from a human; more preferably, the transmembrane domain is the transmembrane domain of hCD28 (human CD28) SEQ ID No: 7.
- the costimulatory signaling domain comprises at least one of the following: CD28, 4-1BB, ICOS, OX40, CD244, Fc ⁇ RI ⁇ , CD8 ⁇ , BTLA, CD27, CD30, GITR, HVEM, DAP10, CD2 Costimulatory signaling domains of NKG2C, LIGHT, and DAP12.
- the costimulatory signaling domain is derived from a human; more preferably, the costimulatory signaling domain is the costimulatory signaling region of hCD28 SEQ ID No: 8.
- the costimulatory signaling domain comprises the costimulatory signaling domain of 4-1BB SEQ ID No: 9. In another embodiment, the costimulatory signaling domain comprises a co-stimulatory signaling domain of CD28 and a costimulatory signaling domain of 4-1BB having the sequence set forth in SEQ ID No: 10.
- the CD3 ⁇ signaling domain has at least 95% of the sequence of SEQ ID No: 11 96%, 97%, 98%, 99% or 100% identity.
- the CD3 ⁇ signaling domain is the protein represented by the sequence of SEQ ID No: 11.
- the chimeric antigen receptor of the invention has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence set forth in SEQ ID No:12. protein.
- the chimeric antigen receptor of the present invention is the sequence of SEQ ID No: 12, each of which is of human origin.
- the chimeric antigen receptor of the invention has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence set forth in SEQ ID No: protein.
- the chimeric antigen receptor of the present invention is the sequence of SEQ ID No: 13, each of which is of human origin.
- the chimeric antigen receptor of the invention has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence set forth in SEQ ID No: 14. protein.
- the chimeric antigen receptor of the present invention is the sequence of SEQ ID No: 14, each of which is of human origin.
- the chimeric antigen receptor of the invention has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence set forth in SEQ ID No: 15. protein.
- the chimeric antigen receptor of the present invention is the sequence shown in SEQ ID No: 15, each of which is of human origin.
- a chimeric antigen receptor of the invention has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence set forth in SEQ ID No: protein.
- the chimeric antigen receptor of the present invention is the sequence of SEQ ID No: 16, each of which is of human origin.
- the chimeric antigen receptor of the invention has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence set forth in SEQ ID No:17. protein.
- the chimeric antigen receptor of the present invention is the sequence of SEQ ID No: 17, each of which is of human origin.
- the invention provides a nucleic acid sequence encoding a chimeric antigen receptor of the invention.
- the invention provides a nucleic acid sequence encoding a chimeric antigen receptor having any one of SEQ ID Nos: 12-17.
- the nucleic acid is the sequence set forth in any one of SEQ ID Nos: 18-23.
- the invention provides a vector comprising the aforementioned nucleic acid sequence.
- the invention provides a T cell expressing the aforementioned chimeric antigen receptor.
- the present invention provides a method of producing the aforementioned T cell, which comprises the step of introducing the aforementioned nucleic acid sequence into a T cell.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the aforementioned carrier or T cell together with a pharmaceutically acceptable carrier, diluent or excipient.
- the invention provides a method of treating a disease associated with PD-L1 or PD-L2 expression, comprising An effective amount of a T cell of the present invention expressing the aforementioned chimeric antigen receptor is administered to an animal.
- the present invention provides the use of the T cell for the preparation of a medicament for treating a PD-L1 or PD-L2 expression-related disease.
- the invention provides the use of the T cell described in the manufacture of a medicament for modulating the immune system.
- the present invention provides the use of the T cell for inhibiting PD-L1 or PD-L2 expression-related cells and treating a related disease.
- Related cells include various tumor cells, such as hematological tumor cells including, but not limited to, leukemia, lymphoma, and/or myeloma, and solid tumors including, but not limited to, lung cancer, gastric cancer, esophageal cancer, colon cancer, breast cancer, ovary Cancer, bladder cancer, renal cell carcinoma, prostate cancer, melanoma, head and neck cancer, glioma, and soft tissue sarcoma; also included in the microenvironment of the tumor, expressing PD-L1 and PD-L2 ligands
- Other cell types include immunosuppressive cells such as macrophages, dendritic cells, and T cells, as well as stromal cells.
- the invention has the advantages that the traditional CAR T cell kills the target cell and has the advantage of the test point drug, that is, the negative negative inhibition pathway is released by the receptor PD-1.
- the existing target of CAR T structure design is a tumor antigen, and the target is to directly kill tumor cells.
- the targeting cells of the present invention include not only tumor cells expressing PD-L1 and/or PD-L2 ligands, but also immunosuppressive cells expressing PD-L1 and/or PD-L2 ligand molecules in the tumor microenvironment and Stromal cells.
- the effect achieved by the technical scheme of the present invention is not only effective killing tumor cells but also anti-tumor immunity of the tumor microenvironment by killing cells expressing PD-L1 and/or PD-L2 ligand in the tumor microenvironment.
- the inhibition of the reaction is beneficial to the anti-tumor effect of the human immune system.
- Figure 1 is a plasmid map of the pCDH-EF1-MCS-T2A-copGFP vector.
- Figure 2 shows the release of cytokine IFN- ⁇ after co-culture of hPD-1-CAR-A T cells and target cells.
- Figure 3 shows the release of cytokine IL-2 after co-culture of hPD-1-CAR-A T cells and target cells.
- Figure 4 shows the killing effect of hPD-1-CAR-A T cells on K562-PD-L1 target cells.
- Figure 5 shows the killing effect of hPD-1-CAR-A T cells on K562-PD-L2 target cells.
- Figure 6 shows inhibition of tumor growth in mice by hPD-1-CAR-A T cells.
- Figure 7 is a plasmid map of the pLVX-EF1 ⁇ -IRES-mCherry vector.
- Figure 8 shows the release of cytokine IL-2 after co-culture of hPD-1-CARs T cells with K562 series target cells, respectively.
- Figure 9 shows the release of cytokine IL-2 after co-culture of hPD-1-CARs T cells with Raji series target cells, respectively. put.
- Figure 10 shows the release of cytokine IFN- ⁇ after co-culture of hPD-1-CARs T cells with K562 series target cells, respectively.
- Figure 11 shows the release of cytokine IFN- ⁇ after co-culture of hPD-1-CARs T cells with Raji series target cells, respectively.
- Figure 12 shows the killing effect of hPD-1-CARs T cells on K562-PDL1 target cells.
- Figure 13 shows the killing effect of hPD-1-CARs T cells on K562-PDL2 target cells.
- Chimeric antigen receptors are engineered receptors that implant any specific receptor into immune effector cells.
- a scFv fragment of a monoclonal antibody that specifically recognizes a tumor antigen is implanted into a T cell, an NK cell, or an NKT cell.
- a nucleic acid encoding a CAR can be introduced into a T cell, an NK cell, or an NKT cell using, for example, a retroviral vector. In this way, a large number of tumor-specific T cells, NK cells or NKT cells can be generated for adoptive cell transfer.
- the target antigen binding domain of the CAR binds to the target antigen
- the activation signal is transmitted into the T cells expressing the CAR through the hinge region and the transmembrane domain, thereby stimulating the immune response of the CAR T cells.
- PD-1 a programmed cell death factor 1
- CD28 a costimulatory molecule belonging to the CD28 family and is expressed inducibly on the surface of activated T cells, B cells and NK cells. Its interaction with its ligand is autoimmune, It plays an important role in transplantation immunity, tumor immunity, and chronic viral infection.
- the extramembranous region of PD-1 used in the present invention is selected from human PD-1, which is 921 bp in length and encodes 288 amino acids, which comprises a conserved IgV domain, and its sequence size starts from amino acid to 125. Amino acid. Mammalian-derived PD-1 protein molecules are highly homologous.
- PD-1 has two ligands that specifically bind to it, PD-L1 and PD-L2.
- PD-L2 and PD- at the genetic level L1 has 37.4% homology.
- PD-L1 is expressed in T cells, B cells, dendritic cells, macrophages, mesenchymal stem cells, and some non-hematopoietic cells (including cardiovascular endothelial cells, renal tubular epithelial cells, glial cells, pancreatic beta cells). , hepatocytes, etc.), PD-L2 is mainly expressed in dendritic cells, monocytes, bone marrow-derived mast cells, and B cells in germinal centers.
- PD-L2 is also found in vascular endothelium and T cells. A small amount of expression. When PD-1 binds to PD-L1/PD-L2, it can inhibit the activation of primary T cells and the function of effector T cells, induce the regulation of T cell production and maintain the regulatory function of T cells. In addition, PD-L1 can also bind to CD80 on APC to suppress the immune response.
- a single-chain antibody variable fragment ie, a single-chain antibody
- VH antibody heavy chain variable region
- VL light chain variable region
- the peptide (Linker) is ligated with a molecular weight of 27-30 kDa, which is the smallest functional structural unit of the antigen binding specificity of the parent antibody.
- the DNA sequence of a single chain antibody can be transformed into a mammalian cell by a viral vector or a specific mammalian expression vector.
- the single-chain antibody gene is fused with other effector gene genes by recombinant DNA technology, and after expression, a single-chain antibody fusion protein having single-chain antibody properties and fused effector protein activity can be obtained.
- the CAR of the present invention may comprise a hinge region, a "domain that binds to the ligand PD-L1 or PD-L2" and a transmembrane domain.
- the hinge region sequence may be, for example, the hinge region of CTLA4, the hinge region of CD28, the hinge region of IgG1, the hinge region of IgG4, the hinge region of IgD, the hinge region of CD7, the hinge region of CD8 ⁇ , the hinge region of PD-1, or the hinge region above. Mutant.
- the hinge region is the hinge region of PD-1 SEQ ID No: 4.
- the spacer may be a short spacer, such as a spacer comprising less than 100, less than 80, less than 60, or less than 45 amino acids.
- the spacer may be or include a hinge region of CTLA4, a hinge region of CD28, a hinge region of IgG1, a hinge region of IgG4, a hinge region of IgD, a hinge region of CD7, a hinge region of CD8 ⁇ , or a hinge region of PD-1 or the above hinge Mutant of the region.
- the transmembrane domain is a CAR sequence spanning the membrane that may comprise a hydrophobic alpha helix.
- the transmembrane domain can be derived from CD28 with good receptor stability.
- the transmembrane domain can be derived from any type I transmembrane protein.
- the transmembrane domain can be a synthetic sequence that is predicted to form a hydrophobic helix.
- the transmembrane domain of the invention may be a mutant derived from the transmembrane domain of CD4, CD7, CD8 ⁇ , CD28, CD134, CD137, Fc ⁇ RI ⁇ , H2-Kb or the above transmembrane domain.
- Intracellular costimulatory signaling region Intracellular domain
- the intracellular domain is the signal transmission part of the CAR. After antigen recognition, the receptors cluster and the signal is transmitted to the cells.
- the most commonly used intracellular domain component is the intracellular domain of CD3 ⁇ containing 3 ITAMs. This transmits an activation signal to the T cells after antigen binding.
- CD3 ⁇ may not provide a sufficient activation signal and may require additional costimulatory signals.
- chimeric CD28 and OX40 can be used with CD3 ⁇ to transmit proliferation/survival signals, or all three can be used together (Pule et al, Molecular therapy, 2005: Volume 12; Issue 5; Pages 933-41).
- the costimulatory signaling region comprises one or more of the following: CD28, 4-1BB, ICOS, OX40, CD244, Fc ⁇ RI ⁇ , CD8 ⁇ , BTLA, CD27, CD30, GITR, HVEM, DAP10, CD2, NKG2C, LIGHT, and DAP12 Co-stimulation signal transduction zone.
- CD28 Preferably, the co-stimulatory signaling region of CD28.
- CD28 is a membrane protein molecule that mediates co-stimulatory signals on the surface of T cells and belongs to the CD28 family.
- CD 28 molecules are constitutively expressed in T cells, and CD 28 plays a leading role in various cascades of co-stimulatory signaling molecules on the surface of T cells, playing the role of "master switch", and is the earliest involved in the activation process of T cells.
- the conjugated co-stimulatory signal plays an important role in the activation of the initial T cells after antigen stimulation, and induces the expression of other co-stimulatory molecules such as ICOS, OX 40, CD 154, and the expression of co-stimulatory molecules.
- the co-stimulatory signal function is exerted in different activation or differentiation stages of T cells and in different micro-environments, thereby initiating a T cell costimulatory signal network to ensure complete and sustained activation of T cells.
- CD28 molecules In human close relatives, such as murine and primate, CD28 molecules also play similar roles and functions.
- 4-1BB (CD137, receptor-induced by lymphocyte ac-tivation) is a newly discovered T cell costimulatory molecule other than CD28/CTLA-4, belonging to the tumor necrosis factor receptor (TNF-R) family.
- TNF-R tumor necrosis factor receptor
- the extracellular domain is rich in cysteine, and the intracellular region contains a potential phosphorylation site. It is not expressed on the surface of resting T cells, but only on activated T cells.
- 4-1BB is also expressed on CD4+, CD25+ regulatory T cells, and 4-1BB plays an important role in lymphocyte activation regulation.
- ⁇ chain means the protein provided by GenBank ID: NM_000734.3, or an equivalent residue to a human close relative; the ⁇ chain is a Receptor-activated protein tyrosine kinase substrate, when the receptor binds to the ligand, the ⁇ chain rapidly undergoes tyrosine phosphorylation and participates in the transduction of lymphocyte activation signals.
- the degree of identity between two amino acid sequences uses the Needle program as in the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al, 2000, Trends in Genetics 16: 276-277). It is preferably determined by the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) performed in version 3.0.0 or higher. The optional parameters used were a gap penalty of 10, a gap extension penalty of 0.5, and an EBLOSUM62 substitution matrix (EMBOSS version of BLOSUM62). Use the output of the Needle tag as "longest identity" (obtained with the -nobrief option) as a percentage identity and calculate as follows:
- the chimeric antigen receptor (CAR) of the present invention replaces the specificity of the monoclonal antibody targeting the tumor antigen of the classical CAR with a similar structure of the extramembranous region of PD-1 or the extramembranous region of PD-1.
- the chimeric antigen receptor of the present invention is capable of specifically binding to a PD-L1 and/or PD-L2 ligand of a target cell.
- the domain (i) which binds to the ligand PD-L1 or PD-L2 may be a domain which binds to a ligand in the PD-1 molecule, or PD-L1 or PD- An scFv of an antibody of L2, such as an antibody of human or animal origin.
- the domain of the chimeric antigen receptor (CAR) of the present invention that binds to the ligand PD-L1 or PD-L2 is the N-terminus of the PD-1 protein represented by the sequence of SEQ ID No: 1. a domain of an immunoglobulin variable region (IgV), or at least 90%, 92%, 95%, 96%, 97%, 98%, 99% or 100% of the protein sequence of SEQ ID No: 1. Variants.
- the variant of the protein of SEQ ID No: 1 in the present invention may be an amino acid change performed outside the IgV domain (positions 25-101 of the amino acid sequence of SEQ ID No: 1), and the change does not affect the domain and the match. The ability of the ligand PD-L1 or PD-L2 to bind.
- the domain that binds to the ligand in the PD-1 molecule has the sequence shown in SEQ ID No: 2 or 3.
- the chimeric antigen receptor of the invention is PD-1 of the sequence set forth in SEQ ID No:
- the N-terminus of the protein comprises a domain sequence of an immunoglobulin variable region (IgV) or a variant thereof, which binds to a hinge molecule, a transmembrane domain, a costimulatory signaling region, and a CD3 ⁇ signaling domain.
- IgV immunoglobulin variable region
- the chimeric antigen receptor of the present invention is a domain having the above sequence of SEQ ID No: 1 or a variant thereof, a hinge region of PD-1 and/or a hinge region of CD8 ⁇ , a transmembrane domain of CD28, CD28 A co-stimulatory signaling region and/or a costimulatory signaling region of 4-1BB, and a receptor molecule composed of a CD3 ⁇ signaling domain. More preferably, the chimeric antigen receptor of the present invention has a sequence as shown in any one of SEQ ID Nos: 12-17 or at least 90%, 95 with the sequence shown in any one of SEQ ID Nos: 12-17. %, 96%, 97%, 98%, 99% or 100% identity protein molecules.
- Variant refers to the inclusion of a change, ie, a substitution, insertion and/or deletion, at one or more (eg, several) positions with the combination of PD-L1 and/or PD-L2 as described herein.
- a polypeptide of a functional chimeric antigen receptor ie, a substitution, insertion and/or deletion
- the invention relates to a variant of the chimeric antigen receptor SEQ ID No: 12-17, a variant of domain (i) of SEQ ID No: 1, SEQ ID No: 11 Variants of the CD3 ⁇ signaling domain are shown, which include a substitution, deletion, and/or insertion at one or more (eg, several) positions.
- the CD3 ⁇ signaling structure represented by SEQ ID No: 12-17 of the chimeric antigen receptor, or the domain (i) represented by SEQ ID No: 1 or SEQ ID No: 11 is introduced.
- the number of amino acid substitutions, deletions, and/or insertions in the domain is no more than ten, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- amino acids may have minor changes in properties, ie, conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; typically smaller deletions of 1-10 amino acids; smaller amino or carboxy terminal extensions , such as an amino terminal methionine residue; a smaller linker peptide of up to 20-25 residues; or a small extension that facilitates purification by changing the net charge or another function, such as a polyhistidine sequence , antigenic epitope or binding domain.
- the variant of domain (i) set forth in SEQ ID No: 1 is the domain (i) of SEQ ID No: 2, and the mutation sites are V64H, L65V, N66V, Y68H, M70E , N74G, K78T, L122V, A125V.
- the variant of domain (i) of SEQ ID No: 1 is the domain (i) of SEQ ID No: 3, and the mutation sites are V64H, L65V, N66V, Y68H, M70E, N74G, K78T, C93A, L122V, A125V.
- conservative substitutions are within the scope of the following groups: basic amino acids (arginine, lysine, and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and day) Asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine) and small amino acids (glycine, alanine, serine) , threonine and methionine).
- Amino acid substitutions that do not generally alter specific activity are known in the art and are, for example, H. Neurath and RL Hill, 1979, The Proteins, New York Academic Publishing (Academic Press, New York).
- amino acid changes have a property that changes the physicochemical properties of the protein.
- amino acid changes can improve the thermal stability of a protein, its ability to bind to a ligand molecule, and the like.
- the essential amino acids in the protein can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine scanning mutagenesis (Cunningham and Wells, 1989, Science 244). :1081-1085). In the latter technique, a single alanine mutation is introduced at each residue in the molecule, and the glucoamylase activity of the resulting mutant molecule is tested to identify amino acids that are critical to the activity of the molecule. Residues. See also Hilton et al., 1996, J. Biol. Chem. 271: 4699-4708.
- the active site of the enzyme or other biological interactions can also be determined by structural physical analysis (as determined by techniques such as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling) in combination with putative amino acid mutations at the contact site. . See, for example, de Vos et al., 1992, Science 255: 306-312; Smith et al., 1992, J. Mol. Biol. 224: 899-904; Wlodaver et al. , 1992, "FEBS Lett.” 309: 59-64.
- the identity of the essential amino acids can also be inferred by comparison with a related protein.
- Single or multiple amino acid substitutions, deletions, and/or insertions can be performed using known methods of mutagenesis, recombination, and/or shuffling followed by relevant screening procedures such as Reidhaar-Olson and Sol ( Sauer), 1988, Science 241: 53-57; Bowie and Sol, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95/17413; or those disclosed in WO 95/22625 to produce and test.
- Other methods that may be used include error-prone PCR, phage display (e.g., Lowman et al, 1991, Biochemistry 30: 10832-10837; U.S. Patent No. 5,223,409; WO 92/06204) and local temptation Change (Derbyshire et al., 1986, Gene 46: 145; Ner et al., 1988, DNA 7: 127).
- a second aspect of the invention relates to a nucleic acid molecule encoding the CAR of the first aspect of the invention.
- the nucleic acid sequence may encode an amino acid sequence corresponding to any one of SEQ ID No: 18-23, but with a different nucleic acid sequence.
- the nucleotide sequence of 1-72 in SEQ ID Nos: 18-23 respectively encodes a signal peptide, and the 73-final nucleotide sequence encodes a mature protein molecule, i.e., a protein molecule represented by SEQ ID Nos: 12-17.
- the invention also provides a vector comprising a nucleic acid sequence according to the invention.
- Such vectors can be used to sequence nucleic acids
- the column is introduced into a host cell such that it expresses and produces a chimeric antigen receptor (CAR) molecule according to the invention.
- CAR chimeric antigen receptor
- the vector may be, for example, a plasmid or a synthetic mRNA or viral vector, such as a retroviral vector or a lentiviral vector.
- the vector may be capable of transfecting or transducing effector cells.
- the invention also provides a host cell comprising a nucleic acid of the invention.
- the host cell may be capable of expressing a CAR according to the first aspect of the invention.
- the host cell can be a human T cell, a human NK cell, or a human NKT cell.
- T cells capable of expressing a CAR according to the present invention can be produced by transducing or transfecting T cells with a nucleic acid encoding CAR.
- the T cell can be an ex vivo T cell, for example, the T cell can be a sample from a peripheral blood mononuclear cell (PBMC).
- PBMC peripheral blood mononuclear cell
- T cells can be activated and/or expanded prior to transduction with a nucleic acid encoding a CAR, for example by treatment with an anti-CD3 monoclonal antibody.
- the invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a vector of the invention or a T cell expressing CAR and a pharmaceutically acceptable carrier, diluent or excipient, and optionally one or more additional pharmaceutically Active polypeptides and/or compounds.
- Such formulations may be, for example, in a form suitable for intravenous infusion.
- T cells expressing the CAR molecule of the present invention are capable of killing cancer cells such as blood cancer and solid tumors.
- Expression can be prepared ex vivo from the patient's own peripheral blood (first party), or from a hematopoietic stem cell transplant from a donor peripheral blood (second party), or from peripheral blood (third party) from an unrelated donor.
- CAR's T cells can be prepared ex vivo from the patient's own peripheral blood (first party), or from a hematopoietic stem cell transplant from a donor peripheral blood (second party), or from peripheral blood (third party) from an unrelated donor.
- CAR's T cells can be derived from ex vivo differentiated cells that can induce stem cells or embryonic stem cells to T cells.
- CAR T cells are generated by introducing DNA or RNA encoding CAR into one of a number of means, including transduction with a viral vector, transfection using DNA or RNA.
- CAR T cells expressing the CAR molecule of the present invention can kill PD-L1/PD-L2 target cells (tumor cells or other immunosuppressive cells) which are immunosuppressive in the tumor microenvironment, and release the tumor microenvironment
- PD-L1/PD-L2 target cells tumor cells or other immunosuppressive cells
- the immunosuppressive effect of the immune system or exogenous immunotherapy program in the body can fully exert anti-tumor immunity, so it can be used for tumor treatment related to the increased expression of PD-L1/PD-L2, due to chronic
- the infection also has an increased expression of PD-L1/PD-L2, and thus the present invention can also be used for the treatment of chronic infectious diseases.
- Tumors associated with elevated PD-L1/PD-L2 expression such as hematological tumors, including but not limited to leukemia, lymphoma, and/or myeloma, as well as solid tumors including, but not limited to, lung cancer, gastric cancer, esophageal cancer , colon cancer, breast cancer, ovarian cancer, bladder cancer, renal cell carcinoma, Prostate cancer, melanoma, head and neck cancer, glioma and soft tissue sarcoma.
- human PD-1 GeneBank ID: L27440.1 gene in GenBank (including PD-1 signal peptide, N-terminal immunoglobulin variable region domain (IgV), and PD-1 hinge region , the transmembrane and intracellular regions of the human CD28 (GenBank ID: AF222341.1) gene, and the ⁇ chain of the human CD3 (GenBank ID: NM_000734.3) gene to construct the PD-1-CD28-CD3 ⁇ of the present invention.
- GenBank ID: 18 The entire sequence (SEQ ID No: 18), which is the coding sequence of the chimeric antigen receptor represented by SEQ ID No: 12 of the present invention.
- the complete nucleic acid sequence of PD-1-CD28-CD3 ⁇ was synthesized (Jin Weizhi Biotechnology Co., Ltd. artificial synthesis), followed by the extramembranous region of human PD-1 gene, the transmembrane region and intracellular region of human CD28 gene, and The intracellular region of the human CD3 gene ⁇ chain.
- the kozak sequence (GCCACC) was introduced at the 5' end, and the EcoR I and BamH I restriction sites were introduced at the 5' and 3' ends, respectively, to form a human PD-1-CD28-CD3 ⁇ nucleic acid with an enzyme cleavage site.
- the full sequence hereinafter referred to as "hPD-1-CAR-A").
- pCDH vector an expression plasmid of hPD-1-CAR-A (hereinafter referred to as "pCDH-CAR-A plasmid") was obtained, and the obtained pCDH-CAR-A plasmid was transformed into DH5 ⁇ strain (purchased from Beijing Huayueyang Biotechnology Co., Ltd.). The sequence was confirmed to be correct by sequencing.
- the pCDH-CAR-A plasmid constructed in Example 2, the pCDH vector plasmid, and the psPAX2 packaging plasmid (purchased from Wuhan Qiling Biotechnology Co., Ltd.) and the pMD2.G packaging plasmid (purchased from Wuhan Yuling Biotechnology Co., Ltd.) will be respectively contained.
- the strains were cultured in large amounts in LB medium, and the pCDH-CAR-A plasmid, pCDH vector plasmid, psPAX2 packaging plasmid and pMD2.G packaging plasmid (using endotoxin-free plasmid) were purchased in large quantities by alkaline lysis. Since Beijing Tiangen Biochemical Technology Co., Ltd.). The obtained plasmid was used for cell transfection.
- Example 4 Packaging, concentration and titer determination of lentivirus
- the amount of reagents and steps required to transfect cells in a 10 cm dish are as follows:
- the transfection reagent obtained in the step 2) was added dropwise to the plasmid mixture of the step 1), and blown to thoroughly mix, and allowed to stand at room temperature for 20 minutes.
- the obtained liposome and plasmid mixture was added dropwise to Lenti-X 293T cells, and shaken and mixed. Incubate at 37 ° C under 5% CO 2 .
- the lentiviral stock solution and the concentrate (purchased from Clontech) were mixed at a ratio of 1:3, and the resulting mixture was precipitated overnight.
- the mixture obtained by precipitating overnight was centrifuged at 1500 g for 45 minutes. After the supernatant was removed, the precipitate was resuspended in a stock volume of X-VIVO (purchased from Lonza) to obtain a concentrated lentivirus.
- the concentrated lentivirus was divided into 100 ul each frozen in a -80 ° C refrigerator.
- Lenti-X 293T cells were infected with the concentrated lentivirus, and after 48 hours of infection, the ratio of expressing GFP cells was measured by flow cytometry.
- the titers of the concentrated pCDH lentivirus and pCDH-CAR-A lentivirus were calculated to be about 1 x 10 8 TU/ml and 1 x 10 8 TU/ml, and the TU was a transducing unit.
- Example 5 In vitro culture, infection and expansion of T cells
- the UBMC cells were infected a second time after the lentivirus infected the UBMC cells for 24 hours.
- the first infected UBMC cells were collected, centrifuged at 1200 rpm for 10 minutes, and the supernatant was carefully aspirated.
- the first infected UBMC cells were resuspended by adding fresh X-VIVO medium containing 10% FBS, and the cell concentration was adjusted to 2 ⁇ 10 6 /ml.
- the obtained UBMC cells were seeded at 0.5 ml/well into a new 24-well plate previously coated with Retronectin, followed by addition of lentivirus concentrate, polybrene and rhIL-2 in the same manner as in step (2).
- the 24-well plate was centrifuged at 1500 g for 90 minutes at 32 ° C, and then placed in an incubator to continue the culture.
- the cells were resuspended and centrifuged at 1200 rpm for 10 minutes, and then seeded in a 24-well plate at a density of 0.3 ⁇ 10 6 /ml. 1ml.
- the cells were expanded by adding 300 IU/ml of rhIL-2, and then changed every 2-3 days, the cell growth density was adjusted to 0.3 ⁇ 10 6 /ml, and the amount of rhIL-2 was the same as before until use.
- the results of the flow cytometry showed that the infection rate of pCDH lentivirus was 53.3%, and the infection rate of pCDH-CAR-A lentivirus was 37.8%.
- Example 6 In vitro co-culture of T cells and target cells, and determination of cytokine release
- Example 5 Infecting T cells with concentrated pCDH lentivirus and pCDH-CAR-A lentivirus, respectively, as shown in Example 5, obtaining T cells infected with pCDH lentivirus (hereinafter referred to as "control T cells”) and T cells infected with pCDH-CAR-A lentivirus (hereinafter referred to as "hPD-1-CAR-A T cells").
- control T cells T cells infected with pCDH lentivirus
- hPD-1-CAR-A T cells T cells infected with pCDH-CAR-A lentivirus
- Flow cytometry by staining with anti-hPD-1 antibody showed that the positive expression rate of hPD-1-CAR-A T cells was 35%, and the ratio detected by GFP was basically the same, ie T
- the cells successfully expressed the chimeric antigen receptor represented by SEQ ID No: 12 of the present invention and were successfully anchored to the surface of T cells.
- K562 ATCC-CCL-243 TM
- K562-PD-L1 and K562-PD-L2 target cell lines were established, respectively.
- the K562-PD-L1 and K562-PD-L2 cell lines were infected with pCDH-hPD-L1 (hPD-L1 GenBank ID: NM_014143.3) and pCDH-hPD-L2 (hPD-L2 GenBank ID: NM_025239) by K562 cell line. .3) Lentivirus, a cell line stably expressing was obtained (methods are the same as in Example 4 and Example 5).
- a 96-well V-well plate was plated with T cells and target cells in an amount of 1 ⁇ 10 4 /100 ⁇ l/well, respectively. The cells were incubated overnight at 37 ° C, 5% CO 2 .
- the culture supernatant was collected after 24 hours, and the obtained supernatant was subjected to ELISA (ELISA kit, purchased from Beijing Dakco is Biotech Co., Ltd.).
- the results showed that the concentration of IFN- ⁇ released by hPD-1-CAR-A T cells after co-culture with K562-PD-L1 or K562-PD-L2 was much higher than that of control T. cell.
- the hPD-1-CAR-A T cells of the invention can effectively increase the killing ability of T cells to tumor cells.
- Example 7 Killing effect of hPD-1-CAR-A T cells on K562-PD-L1 target cells
- T cells were infected with the concentrated pCDH lentivirus and pCDH-CAR lentivirus, respectively, and specific steps were as shown in Example 5 to obtain control T cells and hPD-1-CAR-A T cells.
- the K562-PD-L1 cell line is a cell line stably infected with a lentivirus in which the K562 cell line infects pCDH-hPD-L1.
- the volume of the liquid is 400 ul.
- the 48-well plate was placed in an incubator and cultured overnight.
- hPD-1-CAR-A T cells showed significant specific killing of K562-PD-L1 cells, and with the increase of the ratio of T cells to target cells, the killing rate also followed. A significant increase. When the ratio of T cells to target cells was increased to 10:1, after overnight co-culture, the killing rate reached 65.7%, and the killing effect was very obvious.
- Example 8 Killing effect of hPD-1-CAR-A T cells on K562-PD-L2 target cells
- T cells were infected with concentrated pCDH lentivirus and pCDH-CAR-A lentivirus, respectively, and specific steps were as shown in Example 5 to obtain control T cells and hPD-1-CAR T cells.
- the K562-PD-L1 cell line is a cell line stably expressed by a lentivirus in which p562H-PD-L2 is infected by K562 cells.
- the volume of the liquid is 400 ul.
- the 48-well plate was placed in an incubator for 2.5 hours.
- hPD-1-CAR-A T cells showed significant specific killing of K562-PD-L2 cells, and the kill rate was also increased with the increase of the ratio of T cells to target cells. It has increased significantly. When the ratio of T cells to target cells increased to 10:1, after overnight co-culture, the killing rate reached 45.1%, and the killing effect was very obvious.
- mice 15 mice were ordered, including 1 group of experimental groups (injected hPD-1-CAR-A T cells, as shown in Example 5), 1 group of control groups (injected with control T cells, as shown in Example 5) and 1 Group blanks (with X-VIVO medium as control), 5 mice per group.
- the mouse was a highly immunodeficient mouse (NPG) ordered from Beijing Weitongda Biotechnology Co., Ltd.
- a Raji-PD-L1-luciferase cell line was constructed. On Raji cells (ATCC-CCL-86 TM) PD-L1 expression vector transiently transfected, together with a long-term screening stable puromycin PD-L1 expression in PD-L1-Raji cell line. On this basis, the Raji-PD-L1 cell line was infected with Lenti-luciferase lentivirus, and then Raji-PD-L1-luciferase with dual expression of PD-L1 and luciferase was obtained by flow sorting. Cell line.
- Each mouse was injected with 2 x 10 5 Raji-PD-L1-luciferase cells.
- the above cells were resuspended in 50 ul of PBS, mixed with 50 ul of Matrigel (purchased from BD), and injected into the peritoneal cavity of the mice.
- mice were grouped by mean fluorescence values, with the average fluorescence values of each group being as close as possible.
- 1 x 107 h of PD-1-CAR-A T cells were injected per mouse. The cells were washed once with PBS, resuspended in 200 ul of X-VIVO, and intraperitoneally injected into the tumor of the mouse.
- control T cells For the control group, an equivalent volume of control T cells was injected.
- human PD-1 GeneBank ID: L27440.1 gene in GenBank (including PD-1 signal peptide, N-terminal immunoglobulin variable region domain (IgV), and PD-1 hinge region And its sequence containing partial site mutations (see WO2016/022994A2), the hinge region of human CD8 ⁇ (GenBank ID: NM_001768.6), the transmembrane region and the cell of human CD28 (GenBank ID: AF222341.1) gene The inner region, the human 4-1BB (GenBank ID: U03397.1) intracellular region and the human CD3 (GenBank ID: NM_000734.3) gene ⁇ chain designed the human PD-1 chimeric antigen receptor series Nucleic acid sequence.
- hPD-1-CAR-A has the sequence shown in SEQ ID No: 12. Its corresponding nucleic acid sequence is SEQ ID No: 18.
- hPD-1-CAR-B has the sequence shown in SEQ ID No: 13. Its corresponding nucleic acid sequence is SEQ ID No: 19. Its costimulatory signaling domain comprises the costimulatory signaling domain of CD28 and the costimulatory signaling domain of 4-1BB.
- hPD-1-CAR-C has the sequence shown in SEQ ID No: 14. Its corresponding nucleic acid sequence is SEQ ID No: 20. Its costimulatory signaling domain is a costimulatory signaling domain of 4-1BB.
- hPD-1-CAR-D has the sequence shown in SEQ ID No: 15. Its corresponding nucleic acid sequence is SEQ ID No:21. Its hinge region contains the hinge region of PD1 and the hinge region of CD8 ⁇ .
- hPD-1-CAR-E has the sequence shown in SEQ ID No: 16. Its corresponding nucleic acid sequence is SEQ ID No: 22. Based on hPD-1-CAR-A (SEQ ID No: 12), the binding sites of the binding domain were: V64H, L65V, N66V, Y68H, M70E, N74G, K78T, L122V, A125V. The mutation site of the hinge region is: A131I.
- hPD-1-CAR-F has the sequence shown in SEQ ID No: 17. Its corresponding nucleic acid sequence is SEQ ID No: 23. Based on hPD-1-CAR-A (SEQ ID No: 12), the binding sites of the binding domain were: V64H, L65V, N66V, Y68H, M70E, N74G, K78T, C93A, L122V, A125V. The mutation site of the hinge region is: A131I.
- V64H As an example, it is indicated that the 64th amino acid is mutated from proline to histidine.
- Table 5 Structure and sequence of six human PD-1 chimeric antigen receptors
- hPD-1-CD28-CD3 ⁇ nucleic acid full sequence (hereinafter referred to as "hPD-1-CAR-A", that is, the full nucleic acid sequence of A in Table 5) having the restriction enzyme cleavage site of Example 1 was cloned into pLVX.
- pLVX vector -EF1a-IRES-mCherry lentiviral expression vector
- pLVX vector the expression plasmid of hPD-1-CAR-A was obtained (hereinafter referred to as "pLVX-CAR-A plasmid")
- pLVX-CAR-A plasmid the expression plasmid of hPD-1-CAR-A was obtained
- Stbl3 strain purchasedd from Beijing Huayueyang Biotechnology Co., Ltd.
- the complete nucleic acid sequence of PD-1-CD28-4-1BB-CD3 ⁇ (ie, B in Table 5) was synthesized (Jin Weizhi Biotechnology Co., Ltd.), and the sequence was the extramembranous region of human PD-1 gene, human origin.
- the kozak sequence (GCCACC) was introduced at the 5' end, and the EcoRI and MluI restriction sites were introduced at the 5' and 3' ends, respectively, to form the human PD-1-CD28-4-1BB- with the restriction site.
- the full sequence of the CD3 ⁇ nucleic acid was cloned into the pLVX-EF1a-IRES-mCherry lentiviral expression vector, and the expression plasmid of hPD-1-CAR-B (hereinafter referred to as "pLVX-CAR-B plasmid") was obtained, and the obtained pLVX was obtained.
- the -CAR-B plasmid was transformed into the Stbl3 strain (purchased from Beijing Huayueyang Biotechnology Co., Ltd.). The sequence was confirmed to be correct by sequencing.
- PD1 upstream primer CGGAATTCGCCACCATGCAGATCCCACAGGCG, SEQ ID No: 24
- 3' downstream primer GCCACTGTTACTAGCAAGCTAT, SEQ ID No: 25
- the 5'-end upstream primer (ATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAAACGGGGCAGAAAGAAA, SEQ ID No:26) and the 3'-end downstream primer (CGACGCGTTTAGCGAGGGGGCAGGGCCTGC, SEQ ID No:27) were used, and the pLVX-CAR-B expression plasmid was used as a template for PCR amplification and gel extraction.
- the two fragments recovered by the above-mentioned gelatin were used as templates, 100 ng each, without primers, and PCR amplification for 5 cycles.
- the cut-and-recovered band and the pLVX-EF1a-IRES-mCherry lentiviral expression vector were digested with EcoRI and MluI, and then the digested products were ligated to obtain the hPD-1-CAR-C expression plasmid (hereinafter referred to as " pLVX-CAR-C plasmid"), and the obtained pLVX-CAR-C plasmid was transformed into Stbl3 strain (purchased from Beijing Huayueyang) Biotechnology Co., Ltd.). The sequence was confirmed to be correct by sequencing.
- the Touchdown PCR reaction conditions are as follows:
- the PD1 upstream primer (CGGAATTCGCCACCATGCAGATCCCACAGGCG, SEQ ID No: 24) and the 3'-end PD1 downstream primer (GTGGGCGCCGGTGTTGGTGGTCGCGGCGCTGGCGTCGTGGTGTGGGCTGTGGGCACTTC, SEQ ID No: 28) with the EcoR I restriction site at the 5' end, and the pLVX-CAR-A plasmid as a template , PCR amplification, gel recovery of about 500bp fragment 1.
- the 5' upstream primer (CATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTGTCCAAGTCCCCTATTT, SEQ ID No: 29) and the 3' downstream primer (CGACGCGTTTAGCGAGGGGGCAGGGCCTGC, SEQ ID No: 27) were used for PCR amplification using the pLVX-CAR-A plasmid as a template to recover a fragment 2 of about 700 bp. Fragment 1 was subjected to EcoR I single digestion, and fragment 2 was subjected to MluI single digestion, followed by column recovery of fragment 1 and fragment 2, respectively.
- the pLVX-EF1a-IRES-mCherry vector was double digested with EcoR I and MluI, and the digested vector was recovered. Subsequently, the digested vector was ligated with the digested fragments 1 and 2 recovered from the column to obtain an expression plasmid of hPD-1-CAR-D (hereinafter referred to as "pLVX-CAR-D plasmid"), and The obtained pLVX-CAR-D plasmid was transformed into Stbl3 strain (purchased from Beijing Huayueyang Biotechnology Co., Ltd.). The sequence was confirmed to be correct by sequencing.
- the extracellular sequence of the PD-1 mutant of the sequence E in Table 5 was artificially synthesized, 1-465 bp (Jin Weizhi Biotechnology Co., Ltd. artificial synthesis), and the PD1 upstream primer with the EcoR I restriction site at the 5' end (CGGAATTCGCCACCATGCAGATCCCACAGGCG, SEQ) ID No: 24) and the 3'-end downstream primer (GATCTTGGGGGCCAGGGAGATC, SEQ ID No: 30) were subjected to PCR amplification using the synthesized mutant sequence as a template to obtain a fragment 1 having a size of about 400 bp.
- the 5'-end upstream primer (CTGGCCCCCAAGATCCAGATCAAAGAGAGCCTG, SEQ ID No: 31) and the 3' end The primer (CGACGCGTTTAGCGAGGGGGCAGGGCCTGC, SEQ ID No: 27) was subjected to PCR amplification to obtain a fragment 2 of about 700 bp in size.
- the two fragments recovered by the gelatinization were used as templates, 100 ng each, without primers, and PCR amplification for 5 cycles.
- the recovered band and the pLVX-EF1a-IRES-mCherry lentiviral expression vector were digested with EcoR I and MluI, and then the digested products were ligated to obtain an expression plasmid of hPD-1-CAR-E (hereinafter referred to as "pLVX”.
- pLVX expression plasmid of hPD-1-CAR-E
- Stbl3 strain purchasedd from Beijing Huayueyang Biotechnology Co., Ltd.
- the sequence F in Table 1 is a C93A amino acid mutation based on E, so the construction of the pLVX-CAR-F plasmid was carried out on the basis of the correctly sequenced pLVX-CAR-E plasmid.
- a 5'-end upstream primer CAGCCCGGCCAGGACGCCCGCTTCCGTGTCACA, SEQ ID No: 32
- a 3'-end downstream primer TGTGACACGGAAGCGGGCGTCCTGGCCGGGCTG, SEQ ID No: 33
- the product was digested with DPNI enzyme (purchased from NEB).
- DPNI enzyme purchased from NEB
- the product after digestion of the template was transformed into Stbl3 strain (purchased from Beijing Huayueyang Biotechnology Co., Ltd.), and the sequence mutation was confirmed to be correct by sequencing.
- the plasmid with the correct sequencing (Tiangen Small Plasmid Kit, purchased from Beijing Kainabo Technology Co., Ltd.) was extracted in small amounts, and the mini-extracted plasmid and pLVX-EF1a- were double-digested with EcoR I and Mlu I. IRES-mCherry lentiviral expression vector.
- the obtained digested product was ligated to obtain an expression plasmid of hPD-1-CAR-F (hereinafter referred to as "pLVX-CAR-F plasmid"), and the obtained pLVX-CAR-F plasmid was transformed into Stbl3 strain (purchased From Beijing Huayueyang Biotechnology Co., Ltd.). The sequence was confirmed to be correct by sequencing.
- pLVX-CAR-A the expression plasmids pLVX-CAR-A, pLVX-CAR-B, pLVX-CAR-C, pLVX-CAR-D, pLVX-CAR-E of the human PD-1 chimeric antigen receptor of the present invention are obtained.
- pLVX-CAR-F (hereinafter referred to as "pLVX-CARs plasmid")
- the pLVX-CARs plasmid constructed in Example 10, the pLVX vector plasmid, and the psPAX2 packaging plasmid (purchased from Wuhan Qiling Biotechnology Co., Ltd.) and the pMD2.G packaging plasmid (purchased from Wuhan Qiling Biotechnology Co., Ltd.) will be respectively included.
- the strain was cultured in large amount in LB medium, and pLVX-CARs plasmid, pLVX vector plasmid, psPAX2 packaging plasmid and pMD2.G packaging plasmid (using endotoxin-free plasmid) were extracted by alkaline lysis method. Purchased from Beijing Tiangen Biochemical Technology Co., Ltd.). The obtained plasmid was used for cell transfection.
- the cells were cultured for 24 hours, and transfection was performed when the confluence rate reached 70-90%. Prior to cell transfection, the medium was changed to 10 ml of fresh virus packaging medium Opti-MEM (available from Gibco) containing 5% FBS, 0.2% sodium pyruvate and 1% glutamine.
- Opti-MEM fresh virus packaging medium
- the amount of reagents and steps required to transfect cells in a 10 cm dish are as follows:
- the transfection reagent obtained in the step 2) was added dropwise to the plasmid mixture of the step 1), and blown to thoroughly mix, and allowed to stand at room temperature for 20 minutes.
- the obtained liposome and plasmid mixture was added dropwise to Lenti-X 293T cells, and shaken and mixed. Incubate at 37 ° C under 5% CO 2 .
- the lentiviral stock solution and the concentrate (purchased from Clontech) were mixed at a ratio of 1:3, and the resulting mixture was precipitated at 4 ° C overnight.
- the mixture obtained by overnight precipitation was centrifuged at 1500 g for 45 minutes. After the supernatant was removed, the precipitate was resuspended in a stock solution volume of X-VIVO 15 (purchased from Lonza) to obtain a concentrated lentivirus.
- the concentrated lentivirus was divided into 100 ul each and stored in a -80 ° C refrigerator.
- Lenti-X 293T cells were infected with the concentrated lentivirus, and 48 hours after infection, infected Lenti-X293T cells were collected.
- Lenti-X 293T cells infected with pLVX lentivirus and Lenti-X 293T cells infected with pLVX-CARs lentivirus were immunofluorescently labeled with monoclonal antibody to PD-1 (purchased from BD), followed by flow cytometry The instrument detects the ratio of cells expressing the chimeric antigen receptor.
- TU is the transducing unit
- TU /ml refers to the number of biologically active virus particles contained per milliliter. The titer assay showed that the plasmid-packaged lentivirus could be used for further experiments.
- Plasmid name Titer pLVX 1 ⁇ 10 8 pLVX-CAR-A 1.4 ⁇ 10 8 pLVX-CAR-B 2.5 ⁇ 10 8 pLVX-CAR-C 0.5 ⁇ 10 8 pLVX-CAR-D 0.7 ⁇ 10 8 pLVX-CAR-E 2.92 ⁇ 10 7 pLVX-CAR-F 2.53 ⁇ 10 7
- the UBMC cells were infected a second time after the lentivirus infected the UBMC cells for 24 hours.
- the first infected UBMC cells were collected, centrifuged at 1200 rpm for 10 minutes, and the supernatant was carefully aspirated.
- the first infected UBMC cells were resuspended by adding fresh X-VIVO 15 medium containing 10% FBS, and the cell concentration was adjusted to 2 ⁇ 10 6 /ml.
- the obtained UBMC cells were seeded at 0.5 ml/well into a new 24-well plate previously coated with Retronectin, followed by addition of lentivirus concentrate, polybrene and rhIL-2 in the same manner as in step (2).
- the 24-well plate was centrifuged at 1500 g for 90 minutes at 32 ° C, and then placed in an incubator to continue the culture.
- UBMC cells (hereinafter referred to as "hPD-1-CAR-A T cells") after pLVX-CAR-A lentivirus infection were immunofluorescently labeled with a monoclonal antibody of PD-1 (purchased from BD), and the results showed that The infection rate was 74.01%, and the MOI (multiplicity of infection, the number of viruses infected per cell) was 12.6.
- UBMC cells (hereinafter referred to as "hPD-1-CAR-B T cells") after pLVX-CAR-B lentivirus infection were immunofluorescently labeled with a monoclonal antibody of PD-1 (purchased from BD), and the results showed that The infection rate was 81.84% and the MOI was 47.5.
- UBMC cells (hereinafter referred to as "hPD-1-CAR-C T cells") after pLVX-CAR-C lentivirus infection were immunofluorescently labeled with a monoclonal antibody of PD-1 (purchased from BD), and the results showed that The infection rate was 83.04% and the MOI was 0.72.
- UBMC cells (hereinafter referred to as "hPD-1-CAR-D T cells") after pLVX-CAR-D lentivirus infection were immunofluorescently labeled with a monoclonal antibody of PD-1 (purchased from BD), and the results showed that The infection rate was 56.10% and the MOI was 13.3.
- UBMC cells (hereinafter referred to as "hPD-1-CAR-E T cells") after pLVX-CAR-E lentivirus infection were immunofluorescently labeled with a monoclonal antibody of PD-1 (purchased from BD), and the results showed that The infection rate was 8.73% and the MOI was 4.38.
- UBMC cells (hereinafter referred to as "hPD-1-CAR-F T cells") after pLVX-CAR-F lentivirus infection were immunofluorescently labeled with a monoclonal antibody of PD-1 (purchased from BD), and the results showed that The infection rate was 9.06% and the MOI was 3.8.
- control T cells are UBMC cells (hereinafter referred to as "control T cells") after pLVX lentivirus infection.
- Example 14 In vitro co-culture of T cells and target cells, and determination of cytokine release
- K562 ATCC-CCL-243 TM cell lines were constructed based on K562- luciferase (luciferase GenBank ID: EU581860.1), K562-PD-L1- luciferase (hPD-L1 GenBank ID: NM_014143 .3), K562-PD-L2-luciferase (hPD-L2 GenBank ID: NM_025239.3) target cell line.
- the construction method is that the K562 cell line is infected with pLVX-EF1 ⁇ -luciferase, pLVX-EF1 ⁇ -PD-L1-luciferase, and K562-PD-L2-luciferase, respectively, to obtain stably expressing cells. (Methods are the same as in Example 4 and Example 5).
- a Raji-PD-L1-luciferase cell line was constructed. On Raji cells (ATCC-CCL-86 TM) infection pLVX-EF1 ⁇ -PD-L1- luciferase lentivirus stably expressing PD-L1 of Raji-PD-L1- luciferase cell lines. On Raji cells (ATCC-CCL-86 TM) infection pLVX-EF1 ⁇ -PD-L2- luciferase lentivirus stably expressing PD-L2 to give the Raji-PD-L2- luciferase cell lines.
- the target cell K562-luciferase cell line does not express PD-L1 or PD-L2 on the surface, so hPD-1-CAR-A T cells, hPD-1-CAR-B T cells, hPD-1-CAR -C T cells, hPD-1-CAR-D T cells, hPD-1-CAR-E T cells, hPD-1-CAR-F T cells, hPD-1-CAR-G T cells, hPD-1-CAR -I T cells There is no specific killing effect on the K562-luciferase cell line.
- the K562-PD-L1-luciferase cell line expresses only PD-L1 but not PD-L2, so CAR T cells containing the domain that binds to PD-L1 are K562-PD-L1-luciferase cells. It has a specific killing effect.
- the K562-PD-L2-luciferase cell line does not express PD-L1 on the surface and expresses PD-L2, so CAR T cells containing the domain that binds to PD-L2 are K562-PD-L2-luciferase cells. It has a specific killing effect.
- the Raji-PD-L1-luciferase, Raji-PD-L2-luciferase target cell lines were consistent with K562-PD-L1-luciferase and K562-PD-L2-luciferase cells.
- K562-luciferase K562-PD-L1-luciferase
- K562-PD-L2-luciferase K562-PD-L2-luciferase
- Raji-PD-L1-luciferase Raji-PD-L2-luciferase
- Example 13 The T cells and target cells obtained in Example 13 were separately mixed, and a small number of cells were counted, resuspended in fresh X-VIVO 15 medium, and counted.
- the results showed that the concentration of IL-2 released by hPD-1-CARs T cells co-cultured with K562 series target cells was significantly different from that of control T cells or target cells.
- the concentration of cytokine IL-2 after K562-PD-L2 co-culture was significantly higher than the background value of control T cells or target cells.
- hPD-1-CAR-A T cells, hPD-1-CAR-B T cells, hPD-1-CAR-C T cells, hPD-1-CAR-D T cells successfully expressed the corresponding PD-1
- the chimeric antigen receptors can specifically recognize and bind to the PD-L1 and PD-L2 antigens on the target cells, respectively, and activate the downstream signaling pathway of the CAR to promote the release of the cytokine IL-2.
- the data indicated that hPD-1-CAR-E T cells and hPD-1-CAR-F T cells successfully expressed chimeric antigen receptors containing the corresponding PD-1, but only specifically recognized and bound to target cells.
- the PD-L1 antigen has no effect on the PD-L2 antigen.
- hPD-1-CAR-A T cells and hPD-1-CAR-D T cells were significantly higher in concentration of cytokine IL-2 after co-culture of target cells Raji-PD-L1 or Raji-PD-L2.
- the background value of the control T cell or target cell indicates that hPD-1-CAR-A T cells and hPD-1-CAR-D T cells successfully expressed chimeric antigen receptors containing the corresponding PD-1, and thus each specifically recognizes and binds to target cells.
- PD-L1 and PD-L2 antigens cause activation of the downstream signaling pathway of CAR and promote the release of cytokine IL-2.
- the data indicate that hPD-1-CAR-E T cells successfully express the chimeric antigen receptor containing the corresponding PD-1, but can only specifically recognize and bind the PD-L1 antigen on the target cell to PD-L2. The antigen has no effect.
- the results showed that the concentration of IFN- ⁇ released by hPD-1-CARs T cells co-cultured with K562 series target cells was significantly different from that of control T cells or target cells.
- concentration of cytokine IFN- ⁇ after K562-PD-L2 co-culture was significantly higher than the background value of control T cells or target cells.
- hPD-1-CAR-A T cells, hPD-1-CAR-B T cells, hPD-1-CAR-C T cells, hPD-1-CAR-D T cells successfully expressed the corresponding PD-1
- the chimeric antigen receptors can specifically recognize and bind to the PD-L1 and PD-L2 antigens on the target cells, respectively, and activate the downstream signaling pathway of the CAR to promote the release of the cytokine IFN- ⁇ .
- the results showed that the concentration of IFN- ⁇ released by co-culture of hPD-1-CARs T cells and Raji series target cells was significantly different from that of control T cells or target cells.
- hPD-1-CAR-A T cells, hPD-1-CAR-D T cells co-cultured with target cells Raji-PD-L1 or Raji-PD-L2
- the concentration of IFN- ⁇ was significantly higher than that of the control T cells or target cells. This indicates that hPD-1-CAR-A T cells and hPD-1-CAR-D T cells successfully expressed chimeric antigen receptors containing the corresponding PD-1, and thus each specifically recognizes and binds to target cells.
- PD-L1 and PD-L2 antigens cause activation of the downstream signaling pathway of CAR and promote the release of cytokine IFN- ⁇ .
- the data indicate that hPD-1-CAR-E T cells successfully express the chimeric antigen receptor containing the corresponding PD-1, but can only specifically recognize and bind the PD-L1 antigen on the target cell to PD-L2. The antigen has no effect.
- the six PD-1 chimeric antigen receptors differ in function, hPD-1-CAR-A T cells, hPD-1-CAR-B T cells, hPD-1-CAR-C T cells.
- hPD-1-CAR-D T cells can specifically recognize and bind PD-L1 and PD-L2 antigens on target cells, respectively, and promote the release of cytokines IL-2 and IFN- ⁇ .
- hPD-1-CAR-E T cells and hPD-1-CAR-F T cells can specifically recognize and bind to PD-L1 antigen on target cells, and promote the release of cytokines IL-2IL-2 and IFN- ⁇ .
- Example 15 Killing effect of hPD-1-CARs T cells on target cells
- the hPD-1-CARs T cells were separately mixed with the target cells, and a small number of cells were counted.
- the volume of the culture solution was 100 ul.
- the 96-well plate was placed in an incubator for 6 hours, after which the 96-well plate was taken out from the incubator, and 100 ul of room temperature-balanced steady-Glo luciferase substrate (purchased from Promega) was added to each well.
- the 96-well plate was gently lysed by shaking on a shaker for 15 minutes, and then the fluorescence value was measured using a Victor X Light chemiluminescence detector (available from PerkinElmer Co., Ltd.).
- hPD-1-CAR-E T cells and hPD-1-CAR-F T cells have stronger specific killing effect on target cells containing PD-L1 antigen, and the highest killing efficiency is close to 100%, but No specific killing of target cells containing the PD-L2 antigen.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne un récepteur d'antigène chimère (CAR), son utilisation et son procédé de préparation, un lymphocyte T contenant le récepteur d'antigène chimère, une séquence d'acide nucléique codant pour le récepteur d'antigène chimère, un vecteur comprenant la séquence d'acide nucléique et une composition pharmaceutique comprenant le vecteur ou le lymphocyte T.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611129644.6 | 2016-12-09 | ||
CN201611129644 | 2016-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018103734A1 true WO2018103734A1 (fr) | 2018-06-14 |
Family
ID=62492260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/115184 WO2018103734A1 (fr) | 2016-12-09 | 2017-12-08 | Récepteur d'antigène chimère, son utilisation et son procédé de préparation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018103734A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439632A (zh) * | 2018-11-16 | 2019-03-08 | 中国科学院合肥肿瘤医院 | 一种提高car-t细胞转染效率的方法 |
CN112279922A (zh) * | 2019-07-22 | 2021-01-29 | 北京助天科技发展有限公司 | 一种吞噬细胞嵌合抗原受体及其应用 |
CN113527494A (zh) * | 2020-11-26 | 2021-10-22 | 四川大学华西医院 | 一种新型的抗肿瘤转换受体t细胞 |
CN115427055A (zh) * | 2020-03-09 | 2022-12-02 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153315A (zh) * | 2015-10-09 | 2015-12-16 | 重庆倍思益生物科技有限公司 | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 |
CN105601752A (zh) * | 2016-02-01 | 2016-05-25 | 长沙郝怡雅医药科技有限公司 | 一种多基因重组嵌合抗原受体分子 |
-
2017
- 2017-12-08 WO PCT/CN2017/115184 patent/WO2018103734A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153315A (zh) * | 2015-10-09 | 2015-12-16 | 重庆倍思益生物科技有限公司 | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 |
CN105601752A (zh) * | 2016-02-01 | 2016-05-25 | 长沙郝怡雅医药科技有限公司 | 一种多基因重组嵌合抗原受体分子 |
Non-Patent Citations (1)
Title |
---|
TANG, XIAOLONG ET AL.: "The advantages of PD1 activating chimeric receptor (PD1- ACR) engineered lymphocytes for PDL1+ cancer therapy", AM J TRANSL RES., vol. 7, no. 3, 15 March 2015 (2015-03-15), pages 460 - 473, XP002743491 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439632A (zh) * | 2018-11-16 | 2019-03-08 | 中国科学院合肥肿瘤医院 | 一种提高car-t细胞转染效率的方法 |
CN112279922A (zh) * | 2019-07-22 | 2021-01-29 | 北京助天科技发展有限公司 | 一种吞噬细胞嵌合抗原受体及其应用 |
WO2021013274A3 (fr) * | 2019-07-22 | 2021-03-11 | 北京助天科技发展有限公司 | Récepteur antigénique chimérique et application associée |
CN112279922B (zh) * | 2019-07-22 | 2023-07-28 | 南京助天中科科技发展有限公司 | 一种吞噬细胞嵌合抗原受体及其应用 |
CN115427055A (zh) * | 2020-03-09 | 2022-12-02 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
CN113527494A (zh) * | 2020-11-26 | 2021-10-22 | 四川大学华西医院 | 一种新型的抗肿瘤转换受体t细胞 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7012056B2 (ja) | 養子細胞療法薬を製造するための改善された方法 | |
JP6989634B2 (ja) | B細胞成熟抗原を標的指向するキメラ抗原受容体 | |
CN108018299B (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
CN107429253B (zh) | Cs1靶向性嵌合抗原受体修饰的t细胞 | |
KR20200023165A (ko) | 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용 | |
KR20180042361A (ko) | 통합된 통제가능한 기능들을 가진 키메라 항원 수용체들 | |
CN108004259B (zh) | 靶向b细胞成熟抗原的嵌合抗原受体及其用途 | |
WO2016197570A1 (fr) | Lymphocyte t modifié par le récepteur de l'antigène chimère, et son utilisation | |
WO2018136570A9 (fr) | Récepteurs antigéniques chimériques contre axl ou ror2 et procédés d'utilisation associés | |
BR112016028644B1 (pt) | Método in vitro ou ex vivo para fabricar células t, composição compreendendo um agente de crioproteção e uma população de células efetoras imunes e usos terapêuticos dadita composição | |
WO2018103734A1 (fr) | Récepteur d'antigène chimère, son utilisation et son procédé de préparation | |
WO2019129177A1 (fr) | Cellule t modifiée par récepteur d'antigène chimère modifié par anticorps et leurs utilisations | |
CN108330133B (zh) | 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途 | |
CN107868792B (zh) | 靶向cd123的嵌合抗原受体及其用途 | |
CN112261950A (zh) | 用于治疗cd30+肿瘤的car-cd30 t细胞 | |
CN109320615A (zh) | 靶向新型bcma的嵌合抗原受体及其用途 | |
JP2021525101A (ja) | 改変された抗cd19 car−t細胞 | |
CN113896801B (zh) | 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用 | |
CN113416260B (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
WO2019129174A1 (fr) | Cellule car-t ciblant le cd19 et exprimant un anticorps cd40 à un niveau élevé de stabilité, et son utilisation | |
CN112204133A (zh) | Car nk细胞 | |
WO2021057866A1 (fr) | Anticorps à domaine unique et récepteur antigénique chimérique comprenant une structure d'anticorps | |
WO2020034081A1 (fr) | Récepteur d'antigène chimère visant bcma et ses utilisations | |
CN109438578A (zh) | 嵌合抗原受体及其用途和制备方法 | |
WO2023131285A1 (fr) | Récepteur antigénique chimérique ciblant cldn18.2 et msln et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17877487 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/10/2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17877487 Country of ref document: EP Kind code of ref document: A1 |